The earnings call reflects a balanced outlook for QuidelOrtho. While the company demonstrated strong growth in certain segments and regions, and improved profitability metrics, it also faced challenges such as a decline in North America revenue and decreased COVID-related revenue. The solid performance outside North America and improved profitability metrics are counterbalanced by the revenue declines in North America and COVID segments.

Company Guidance

During the QuidelOrtho Second Quarter 2025 Financial Results Conference Call, the company provided several key metrics and guidance for the remainder of the year. Total revenue for Q2 was $614 million, reflecting a 1% growth, excluding COVID and Donor Screening businesses. The Labs and Immunohematology business units reported organic constant currency growth of 5% and 3%, respectively. Adjusted EBITDA margin improved by 330 basis points, and adjusted diluted EPS showed significant improvement compared to the previous year. For the full year 2025, QuidelOrtho maintained its financial guidance, expecting total revenue between $2.6 billion and $2.81 billion and adjusted EBITDA between $575 million and $615 million. The company foresees a lower COVID revenue range of $70 million to $100 million, down from previous estimates due to less severe current COVID strains. Additionally, tariff headwinds are now estimated to be $20 million to $25 million, down from prior estimates. The company also highlighted its molecular strategy, including the proposed acquisition of LEX Diagnostics, which could present growth opportunities if the Velo molecular platform receives FDA clearance.

Consistent Growth in Labs and Immunohematology

The Labs business delivered a 5% organic growth, while the Immunohematology business achieved a 3% growth, showing strong performance in key segments.

Strong Performance Outside North America

The company's OUS (Outside the United States) performance was robust with 14% growth in Latin America, 6% growth in Japan and Asia Pacific, and 3% growth in Europe, Middle East, and Africa (EMEA).

Improved Profitability Metrics

Adjusted EBITDA margin improved by 330 basis points year-over-year, and adjusted diluted EPS grew by 271% compared to the previous year.

Potential in China Market

Despite global challenges, China revenue grew by 2% in Q2, with low penetration in the market presenting a significant growth opportunity.

Successful ERP System Conversion

The ERP system conversion related to the business combination was completed successfully, promising lower integration costs in future.

QuidelOrtho (QDEL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

QDEL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	0.50 / -	0.85	―	―	―
Aug 05, 2025	2025 (Q2)	<0.01 / 0.12	-0.07	271.43% (+0.19)
May 07, 2025	2025 (Q1)	0.59 / 0.74	0.44	68.18% (+0.30)
Feb 12, 2025	2024 (Q4)	0.59 / 0.63	1.17	-46.15% (-0.54)
Nov 07, 2024	2024 (Q3)	0.27 / 0.85	0.9	-5.56% (-0.05)
Jul 31, 2024	2024 (Q2)	-0.23 / -0.07	0.26	-126.92% (-0.33)
May 08, 2024	2024 (Q1)	0.39 / 0.44	1.8	-75.56% (-1.36)
Feb 13, 2024	2023 (Q4)	2.04 / 1.17	1.76	-33.52% (-0.59)
Nov 01, 2023	2023 (Q3)	0.60 / 0.90	1.85	-51.35% (-0.95)
Aug 08, 2023	2023 (Q2)	0.28 / 0.26	2.34	-88.89% (-2.08)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

QDEL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$23.68	$23.44	-1.01%
May 07, 2025	$25.85	$36.46	+41.04%
Feb 12, 2025	$39.94	$41.65	+4.28%
Nov 07, 2024	$38.85	$43.75	+12.61%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.